Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Geometrical dilution rows showed characteristic dose response curves. After clot formation a rapid lysis was seen with all plasminogen activators. The 50% lysis time correlated to the plasminogen activator dose and showed no differences among normal adults, children aged 1-6 years, and children age 7-14 years. Newborns demonstrated a significantly prolonged 50% lysis time with all urokinase concentrations. The 50% lysis time with recombinant tissue plasminogen activator and streptokinase was significantly prolonged only at high concentrations, whereas we could not see any differences at lower concentrations. CONCLUSION: The experience with thrombolytic agents in newborns is limited, and no controlled investigations have been reported. Our results of the fibrinolytic potential in a plasma milieu in vitro after adding different plasminogen activators can be helpful to establish dosage guidelines for thrombolytic therapy in newborns and older children.
|
Authors | M Ries, M Zenker, J Klinge, H Keuper, D Harms |
Journal | Journal of pediatric hematology/oncology
(J Pediatr Hematol Oncol)
Vol. 17
Issue 3
Pg. 260-4
(Aug 1995)
ISSN: 1077-4114 [Print] United States |
PMID | 7620925
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- Streptokinase
- Plasminogen Activators
- Urokinase-Type Plasminogen Activator
|
Topics |
- Adolescent
- Adult
- Age Factors
- Child
- Child, Preschool
- Fibrinolysis
(drug effects)
- Humans
- In Vitro Techniques
- Infant, Newborn
- Plasminogen Activators
(pharmacology)
- Platelet Aggregation
(drug effects)
- Recombinant Proteins
(pharmacology)
- Streptokinase
(pharmacology)
- Urokinase-Type Plasminogen Activator
(pharmacology)
|